The study’s lead author, Dr. Robert Fortuna, a professor specializing in Primary Care and Pediatrics, underscores that the program’s success hinged on more than just increasing the number of patients screened. The team’s comprehensive framework ensured that once patients were identified as eligible, they were systematically enrolled into a robust clinical program guaranteeing annual low-dose CT follow-ups. This sustained engagement represents a clinical gold standard, elevating lung cancer screening from a one-time intervention to an ongoing care pathway that can systematically reduce lung cancer mortality.

Lung cancer screening guidelines, formalized in 2013, recommend annual low-dose computed tomography scans for individuals aged 50 to 80 who have a significant history of smoking—specifically, at least 20 pack-years. Yet, implementing these criteria broadly has proven complex due to the nuanced nature of smoking histories and insufficient capture of detailed smoking data in electronic health records (EHRs). Unlike breast or colon cancer screening, which rely primarily on age or straightforward demographic markers, lung cancer screening criteria demand precise quantification of lifetime tobacco exposure, which fluctuates over an individual’s history and is often incompletely documented.

To navigate these complexities, URMC leveraged informatics expertise to develop a bespoke algorithm integrated into their EHR systems. This algorithm meticulously computed pack-year histories by pulling together scattered data points—such as patient-reported smoking intensity, duration, quit dates, and historical notes—enabling accurate eligibility assessments on a daily basis. Each morning, primary care providers across 42 network practices received lists highlighting which patients scheduled for appointments qualified for lung cancer screening, aligning lung cancer screening workflows with more established cancer prevention programs like mammography and colonoscopy.

This targeted outreach, however, was complemented by real-time clinical decision support alerts that prompted providers during patient encounters to discuss screening or smoking cessation counseling. Such reminders transformed the clinical environment into one that actively fosters screening conversations rather than passively relying on patient presentation or clinician discretion. Critically, these electronic nudges were paired with well-coordinated multidisciplinary collaboration spanning primary care, pulmonology, radiology, thoracic

The impetus for the CHANCES trial lies in a critical global health challenge: the persistent lack of high-quality, population-based data from developing countries, where cancer detection rates lag behind those in wealthier nations. By enrolling over 100,000 participants aged 50 to 74 across 25 Chinese provinces, this study seeks to bridge a significant gap in knowledge. Its findings promise to inform both national and international cancer screening strategies that are culturally relevant, economically viable, and clinically effective.

At the heart of the study is the evaluation of lung cancer screening approaches, particularly the use of low-dose computed tomography (LDCT), a relatively newer technology shown to detect pulmonary nodules at much earlier stages. The trial carefully compares the effects of annual versus biennial LDCT scans on lung cancer-specific mortality, offering critical insight into the frequency that balances benefit, harm, and cost. Prior studies, mostly conducted in high-income countries, have suggested LDCT’s potential, but data from large, diverse populations within developing countries have remained scarce until now.

Simultaneously, the trial addresses colorectal cancer (CRC), a leading cause of cancer-related death worldwide and one that is highly amenable to screening interventions. The CHANCES trial integrates varied screening methods—ranging from colonoscopy to fecal immunochemical testing (FIT)—to assess their relative effectiveness and feasibility within the Chinese healthcare landscape. Notably, participants with positive FIT results are advised to undergo diagnostic colonoscopy, reflecting a pragmatic, stepped approach to screening that balances sensitivity and patient compliance.

Randomization into three groups allows the researchers to tease apart complex interactions between screening modalities. The first group will receive five consecutive annual LDCT scans combined with a single screening colonoscopy, aiming to maximize early detection of both lung and colorectal cancers. The second arm involves participants undergoing three biennial LDCT scans alongside five annual FIT tests, combining imaging and biochemical methods to optimize sensitivity while potentially reducing the burden of more invasive procedures. The third group evaluates a more conventional approach, with participants opting for either one colonoscopy or five annual FIT tests alone, serving as a critical comparator arm.

Such rigorous design is revolutionary considering the scale—105,600 participants—and the diversity of screening schedules tested, making CHANCES a rare opportunity to generate high-powered data with immediate public health relevance. The trial is not only focused on clinical outcomes, primarily lung cancer-specific mortality, but is also committed to meticulous cost-effectiveness analysis, a vital component for countries with constrained healthcare budgets aiming to implement sustainable screening programs.

Statistically powered and methodologically robust, the CHANCES trial stands out as the first of its kind to systematically evaluate the mortality reduction potential of annual and biennial LDCT screening in a randomized controlled setting, particularly within an Asian population. This aspect is critical because lung cancer risk profiles, environmental exposures, and healthcare resource availability vary considerably across settings, meaning existing evidence from Western populations might not be directly applicable.

Beyond lung cancer, the integrated screening approach reflects an innovative model that leverages synergies between lung and colorectal cancer programs, potentially streamlining resource use and patient engagement. Such dual-focused models could become templates for other regions grappling with multiple high-burden cancers, enhancing the efficiency of national cancer control strategies.

The trial’s methodology includes comprehensive follow-up to track both cancer incidence and mortality outcomes over its five-year span. This longitudinal perspective will help elucidate not only immediate detection rates but also the long-term impact of screening on survival, morbidity, and quality of life. Furthermore, the inclusion of participants across 25 provinces ensures that findings encapsulate regional variations in cancer risk factors, screening acceptability, and healthcare infrastructure, enriching the external validity of the results.

A critical element of success for CHANCES lies in participant adherence, especially given the complexity of screening schedules across arms. The researchers plan to monitor compliance meticulously, with patient education and community engagement forming integral components of the trial’s operational framework. These efforts underscore the balance between scientific rigor and real-world applicability that this trial embodies.

Moreover, the trial’s registration with the Chinese Clinical Trial Registry (ChiCTR1900025257) and transparent reporting align with global best practices, fostering trust and paving the way for data sharing and collaborative research. This openness is crucial for translating trial insights into public health action not only within China but also in other developing nations seeking evidence-informed screening guidelines.

If successful, the CHANCES trial could signal a paradigm shift, prompting reconsideration of lung cancer screening intervals and integration strategies that marry imaging and biochemical testing. Such data-driven guidance is particularly essential as nations worldwide face the dual challenges of rising cancer incidence and limited healthcare resources.

Given that lung and colorectal cancers remain among the deadliest malignancies globally, improvements in early detection via optimized screening efforts can translate directly into millions of lives saved and reduced economic burden from advanced-stage treatments. The CHANCES trial’s comprehensive approach, exploring both clinical effectiveness and cost-effectiveness, ensures that its findings will have pragmatic resonance.

In anticipation of the trial outcomes, healthcare policymakers, providers, and patient advocacy groups are watching closely. The potential to offer evidence-based recommendations, tailored to the unique needs of populations within developing settings, carries profound implications. Importantly, successful screening programs grounded in CHANCES’ data may catalyze increased public awareness and engagement, driving healthier behaviors and earlier healthcare seeking.

This research taps into a moment when cancer control efforts are rapidly evolving, fueled by technological advancements and a growing global consensus on the importance of screening. Yet, high-quality, context-specific data have remained elusive, making CHANCES a beacon of hope for bridging this divide.

As the trial progresses, challenges are inevitable—from logistical complexities to ensuring equitable access across diverse provinces—but the multidisciplinary research team appears well-prepared to address these hurdles, leveraging China’s expansive healthcare infrastructure and commitment to innovation.

In sum, the CHANCES trial represents a pivotal step forward for cancer prevention science, synergizing rigorous clinical methodology with public health imperatives. Its insights promise to resonate well beyond China’s borders, inspiring similar large-scale endeavors worldwide and setting new standards for integrated cancer screening programs in resource-limited settings.

The future of early cancer detection could very well hinge on the outcomes of such bold, comprehensive studies. By rigorously exploring lung and colorectal cancer screening side by side, the CHANCES trial is charting a course toward smarter, more effective strategies that could save countless lives and reshape global approaches to cancer control.

Subject of Research: Comparison of screening strategies for lung cancer and colorectal cancer in the Chinese population through a randomized controlled trial.

Article Title: A study protocol for the CHinA National CancEr screening (CHANCES) trial: a randomized controlled study to compare the screening strategies for lung cancer and colorectal cancer.

Article References:
Gao, Y., Hu, P., Wu, N. et al. A study protocol for the CHinA National CancEr screening (CHANCES) trial: a randomized controlled study to compare the screening strategies for lung cancer and colorectal cancer. BMC Cancer 25, 727 (2025). https://doi.org/10.1186/s12885-025-14152-6

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14152-6